SynthesisFrontiers in oncology2026
Global pattern and evolution of PPARγ in breast cancer: a 25-Year bibliometric and visualized knowledge map analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bibliometric methods were employed to visually examine the global trends and progression of PPARγ in the breast with the aim of clarifying the evolution of significant academic contributions, collaborative networks, foundational disciplines, and key terms. A comprehensive search was conducted on publications related to PPARγ in breast cancer research using the Web of Science Core Collection database (WOSCC) and PubMed. The reference types for the WOSCC database were restricted to articles and reviews published in English, whereas PubMed focused on randomized controlled trials (RCTs). Data visualization and analysis were conducted using bibliometric tools, including CiteSpace, VOSviewer, Bibliometrix, and Scimago Graphica. Sensitivity analysis for non-deterministic indicators and bias risk assessment of RCTs were also conducted. A total of 1,391 publications and 3 RCTs were included in this study. The annual growth rate of publications in this field was 3.54%. The primary contributing countries were the United States, China, Japan, and Italy. The top three authors with the highest academic contributions were Catalano, Stefania, Bonofiglio, Daniela, and Ando, Sebastiano, which were also the most frequently cited authors. The most frequent keywords were PPARγ, breast cancer, apoptosis, and expression. This study provides the first bibliometric overview of PPARγ research in breast cancer, highlighting a continuous increase in scholarly output, with major contributions from Europe, the Americas, and Asia. The discipline has gradually evolved from initial basic and preclinical studies to exploring the complex regulatory system of the "cancer - metabolism - immunity" interaction network. Currently, the effectiveness of conventional PPARγ agonists in clinical trials is still limited, highlighting the urgent need and potential for the clinical development of highly selective PPARγ modulators. This review aims to deepen our understanding of the role of PPARγ in breast cancer, support the translation of related research into clinical practice, and offer a theoretical basis and directional guidance for future advancements in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.